Search

Your search keyword '"Manwani, Deepa"' showing total 350 results
Start Over Author "Manwani, Deepa" Publication Type Academic Journals
350 results on '"Manwani, Deepa"'

4. COVID-19 mRNA vaccination responses in individuals with sickle cell disease: an ASH RC Sickle Cell Research Network Study

Author

Anderson, Alan R., Andemariam, Biree, Brandow, Amanda, Campbell, Andrew, Cohen, Alice, Darbari, Deepika, El Rassi, Fuad, ield, Joshua, Fung, Ellen, Gee, Beatrice, Ibrahim, Ibrahim, Idowu, Modupe, Kanter, Julie, Klings, Elizabeth S., King, Allison, Kutlar, Abdullah, Lebensburger, Jeffrey D., Leavey, Patrick, Liem, Robert I., Manwani, Deepa, Narang, Shalu, Pace, Betty, Quinn, Charles T., Rivlin, Kenneth, Strouse, John J., Thompson, Alexis A., Tubman, Venée N., Vichinsky, Elliot, Walters, Mark, Brandow, Amanda M., Vichinsky, Elliott, Leavey, Patrick J., Nero, Alecia, Ibrahim, Ibrahim F., Field, Joshua J., Baer, Amanda, Soto-Calderon, Haideliza, Vincent, Lauren, Zhao, Yan, Santos, Jefferson J. S., Hensley, Scott E., Mortier, Nicole, Lanzkron, Sophie, Neuberg, Donna, and Abrams, Charles S.

Published
2024
Full Text
View/download PDF

6. Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects

Author

Kanter, Julie, Smith, Wally R, Desai, Payal C, Treadwell, Marsha, Andemariam, Biree, Little, Jane, Nugent, Diane, Claster, Susan, Manwani, Deepa G, Baker, Judith, Strouse, John J, Osunkwo, Ifeyinwa, Stewart, Rosalyn W, King, Allison, Shook, Lisa M, Roberts, John D, and Lanzkron, Sophie

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Health Services, Pain Research, Clinical Research, Sickle Cell Disease, Hematology, Rare Diseases, Good Health and Well Being, Adult, Anemia, Sickle Cell, Child, Health Services Accessibility, Hematologic Diseases, Humans, United States, Cardiovascular medicine and haematology
Abstract

Sickle cell disease (SCD) is the most common inherited blood disorder in the United States. It is a medically and socially complex, multisystem illness that affects individuals throughout the lifespan. Given improvements in care, most children with SCD survive into adulthood. However, access to adult sickle cell care is poor in many parts of the United States, resulting in increased acute care utilization, disjointed care delivery, and early mortality for patients. A dearth of nonmalignant hematology providers, the lack of a national SCD registry, and the absence of a centralized infrastructure to facilitate comparative quality assessment compounds these issues. As part of a workshop designed to train health care professionals in the skills necessary to establish clinical centers focused on the management of adults living with SCD, we defined an SCD center, elucidated required elements of a comprehensive adult SCD center, and discussed different models of care. There are also important economic impacts of these centers at an institutional and health system level. As more clinicians are trained in providing adult-focused SCD care, center designation will enhance the ability to undertake quality improvement and compare outcomes between SCD centers. Activities will include an assessment of the clinical effectiveness of expanded access to care, the implementation of SCD guidelines, and the efficacy of newly approved targeted medications. Details of this effort are provided.

Published
2020

14. Hemolysis dictates monocyte differentiation via two distinct pathways in sickle cell disease vaso-occlusion

Author

Liu, Yunfeng, Su, Shan, Shayo, Sarah, Bao, Weili, Pal, Mouli, Dou, Kai, Shi, Patricia A., Aygun, Banu, Campbell-Lee, Sally, Lobo, Cheryl A., Mendelson, Avital, An, Xiuli, Manwani, Deepa, Zhong, Hui, and Yazdanbakhsh, Karina

Subjects
Thermo Fisher Scientific Inc., Hemolysis and hemolysins, Sickle cell anemia, Scientific equipment and supplies industry, Viral antibodies, Heme, Macrophages, Antibodies, Health care industry, New York Blood Center
Abstract

Sickle cell disease (SCD) is a hereditary hemoglobinopathy characterized by painful vaso-occlusive crises (VOC) and chronic hemolysis. The mononuclear phagocyte system is pivotal to SCD pathophysiology, but the mechanisms governing monocyte/macrophage differentiation remain unknown. This study examined the influence of hemolysis on circulating monocyte trajectories in SCD. We discovered that hemolysis stimulated CSF-1 production, partly by endothelial cells via Nrf2, promoting classical monocyte (CMo) differentiation into blood patrolling monocytes (PMo) in SCD mice. However, hemolysis also upregulated CCL-2 through IFN-I, inducing CMo transmigration and differentiation into tissue monocyte-derived macrophages. Blocking CMo transmigration by anti-P selectin antibody in SCD mice increased circulating PMo, corroborating that CMo-to-tissue macrophage differentiation occurs at the expense of CMo-to-blood PMo differentiation. We observed a positive correlation between plasma CSF-1/CCL-2 ratios and blood PMo levels in patients with SCD, underscoring the clinical significance of these two opposing factors in monocyte differentiation. Combined treatment with CSF-1 and anti-P selectin antibody more effectively increased PMo numbers and reduced stasis compared with single-agent therapies in SCD mice. Altogether, these data indicate that monocyte fates are regulated by the balance between two heme pathways, Nrf2/CSF-1 and IFN-I/CCL-2, and suggest that the CSF-1/CCL-2 ratio may present a diagnostic and therapeutic target in SCD., Introduction Sickle cell disease (SCD) is characterized by hemolytic anemia and painful vaso-occlusive crises (VOC), caused by increased adherence of sickle RBCs to the underlying activated vascular endothelium (1, 2) [...]

Published
2023
Full Text
View/download PDF

15. Global geographic differences in healthcare utilization for sickle cell disease pain crises in the CASiRe cohort

Author

Strunk, Crawford, Tartaglione, Immacolata, Piccone, Connie M., Colombatti, Raffaella, Andemariam, Biree, Manwani, Deepa, Smith, Ashya, Haile, Haikel, Kim, Esther, Wilson, Samuel, Asare, Eugenia Vicky, Rivers, Angela, Farooq, Fatimah, Urbonya, Rebekah, Boruchov, Donna, Boatemaa, Gifty Dankwah, Perrotta, Silverio, Ekem, Ivy, Sainati, Laura, Rao, Sudha, Zempsky, William, Sey, Fredericka, Antwi-Boasiako, Charles, Segbefia, Catherine, Inusa, Baba, and Campbell, Andrew D.

Published
2021
Full Text
View/download PDF

16. Age of first pain crisis and associated complications in the CASiRe international sickle cell disease cohort

Author

Tartaglione, Immacolata, Strunk, Crawford, Antwi-Boasiako, Charles, Andemariam, Biree, Colombatti, Raffaella, Asare, Eugenia Vicky, Piccone, Connie M., Manwani, Deepa, Boruchov, Donna, Tavernier, Fitz, Farooq, Fatimah, Akatue, Sophia, Oteng, Bianca, Urbonya, Rebekah, Wilson, Samuel, Owda, Ahmed, Bamfo, Rose, Boatemaa, Gifty Dankwah, Rao, Sudha, Zempsky, William, Sey, Fredericka, Inusa, Baba PD, Perrotta, Silverio, Segbefia, Catherine, and Campbell, Andrew D.

Published
2021
Full Text
View/download PDF

22. Draining Vein Thrombosis of Developmental Venous Anomaly in Sickle Cell Trait Patients: A Case Report and a Literature Review.

Author

Essibayi, Muhammed Amir, Liriano, Genesis, Strumph, Kaitlin L., Manwani, Deepa, Behbahani, Mandana, and Altschul, David J.

Subjects
VENOUS thrombosis, MAGNETIC resonance imaging, CHILD patients, SUNSHINE, SINUS thrombosis, SICKLE cell trait
Abstract

Introduction: Cerebral venous sinus thrombosis (CVST) is a rare but serious condition in both adults and children. Risk factors include thrombophilias, dehydration, and certain inherited conditions like sickle cell trait (SCT). We present a case of CVST in a pediatric patient with SCT to highlight key considerations in diagnosis and management. Case Presentation: A 14-year-old male with SCT presented with worsening headache and vomiting after prolonged sun exposure and dehydration during athletic camp. Imaging revealed right occipital hemorrhage, hydrocephalus, right CSVT, and bilateral cerebellar developmental venous anomalies. Hypercoagulability testing was normal. Diagnostic evaluation included computed tomography, magnetic resonance imaging, MR venography (MRV), and hypercoagulability testing. The patient was treated with an external ventricular drain, platelet transfusion, and anticoagulation. Management also involved hydration, platelet transfusion, supportive care, and multidisciplinary follow-up. Follow-up MRV showed recanalization. Conclusion: This case highlights SCT as a potential CVST risk factor. Timely recognition, evaluation of precipitants like dehydration, supportive care including anticoagulation, and multidisciplinary management are important. An individualized approach is needed to balance thrombosis recurrence and bleeding risks. Patients with SCT require education on risks and prompt evaluation of neurological symptoms to allow early diagnosis and care of CVST. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. An Analysis of Racial and Ethnic Backgrounds Within the CASiRe International Cohort of Sickle Cell Disease Patients: Implications for Disease Phenotype and Clinical Research

Author

Campbell, Andrew D., Colombatti, Raffaella, Andemariam, Biree, Strunk, Crawford, Tartaglione, Immacolata, Piccone, Connie M., Manwani, Deepa, Asare, Eugenia Vicky, Boruchov, Donna, Farooq, Fatimah, Urbonya, Rebekah, Boatemaa, Gifty Dankwah, Perrotta, Silverio, Sainati, Laura, Rivers, Angela, Rao, Sudha, Zempsky, William, Sey, Fredericka, Segbefia, Catherine, Inusa, Baba, and Antwi-Boasiako, Charles

Published
2021
Full Text
View/download PDF

25. A study of the geographic distribution and associated risk factors of leg ulcers within an international cohort of sickle cell disease patients: the CASiRe group analysis

Author

Antwi-Boasiako, Charles, Andemariam, Biree, Colombatti, Raffaella, Asare, Eugenia Vicky, Strunk, Crawford, Piccone, Connie M., Manwani, Deepa, Boruchov, Donna, Farooq, Fatimah, Urbonya, Rebekah, Wilson, Samuel, Boatemaa, Gifty Dankwah, Perrotta, Silverio, Sainati, Laura, Rivers, Angela, Rao, Sudha, Zempsky, William, Ekem, Ivy, Sey, Fredericka, Segbefia, Catherine, Inusa, Baba, Tartaglione, Immacolata, and Campbell, Andrew D.

Published
2020
Full Text
View/download PDF

27. Evaluating thromboprophylaxis in the sickle cell disease population: Navigating the evidence gap.

Author

Davila, Jennifer, O'Brien, Sarah H., Mitchell, William B., and Manwani, Deepa

Subjects
SICKLE cell anemia, EVIDENCE gaps, CELL populations, THROMBOEMBOLISM, HEMOLYTIC anemia
Abstract

Summary: Sickle cell disease (SCD) arises from beta‐globin gene mutations, with global estimates indicating around 500 000 affected neonates in 2021. In the United States, it is considered rare, impacting fewer than 200 000 individuals. The key pathogenic flaw lies in mutant haemoglobin S, prone to polymerization under low oxygen conditions, causing erythrocytes to adopt a sickled shape. This leads to complications like vascular occlusion, haemolytic anaemia, inflammation and organ damage. Beyond erythrocyte abnormalities however, there is a body of literature highlighting the hypercoagulable state that is likely a contributor to many of the complications we see in SCD. The persistent activation of the coagulation cascade results in thromboembolic events, notably venous thromboembolism (VTE) which is independently associated with increased mortality in both adults and children with SCD. While the increased risk of VTE in the SCD population seems well established, there is a lack of guidelines for thromboprophylaxis in this population. This Wider Perspective will describe the hypercoagulable state and increased thrombosis risk in the SCD population, as well as advocate for the development of evidence‐based guidelines to aid in the prevention of VTE in SCD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Pain Frequency and Health Care Utilization Patterns in Women with Sickle Cell Disease Experiencing Menstruation-Associated Pain Crises.

Author

Segbefia, Catherine, Campbell, Jillian, Tartaglione, Immacolata, Asare, Eugenia Vicky, Andemariam, Biree, Zempsky, William, Colombatti, Raffaella, Boatemaa, Gifty Dankwah, Boruchov, Donna, Rao, Sudha, Piccone, Connie M., Smith, Ashya, Haile, Haikel, Kim, Esther, Wilson, Samuel, Farooq, Fatimah, Urbonya, Rebekah, Rivers, Angela, Manwani, Deepa, and Gai, Jiaxiang

Subjects
SICKLE cell anemia treatment, TREATMENT of dysmenorrhea, PAIN measurement, CROSS-sectional method, SELF-evaluation, ACQUISITION of data, MEDICAL care use, SEVERITY of illness index, COMPARATIVE studies, DYSMENORRHEA, RESEARCH funding, QUESTIONNAIRES, MEDICAL records, HOSPITAL care, DESCRIPTIVE statistics, MEDICAL appointments, SICKLE cell anemia, LONGITUDINAL method, DISEASE complications
Abstract

Background: Pain crises in sickle cell disease (SCD) lead to high rates of health care utilization. Historically, women have reported higher pain burdens than men, with recent studies showing a temporal association between pain crisis and menstruation. However, health care utilization patterns of SCD women with menstruation-associated pain crises have not been reported. We studied the frequency, severity, and health care utilization of menstruation-associated pain crises in SCD women. Materials and Methods: A multinational, cross-sectional cohort study of the SCD phenotype was executed using a validated questionnaire and medical chart review from the Consortium for the Advancement of Sickle Cell Research (CASiRe) cohort. Total number of pain crises, emergency room/day hospital visits, and hospitalizations were collected from a subcohort of 178 SCD women within the past 6 months and previous year. Results: Thirty-nine percent of women reported menstruation-associated pain crises in their lifetime. These women were significantly more likely to be hospitalized compared with those who did not (mean 1.70 vs. 0.67, p = 0.0005). Women reporting menstruation-associated pain crises in the past 6 months also experienced increased hospitalizations compared with those who did not (mean 1.71 vs. 0.75, p = 0.0016). Forty percent of women reported at least four menstruation-associated pain crises in the past 6 months. Conclusions: Nearly 40% of SCD women have menstruation-associated pain crises. Menstruation-associated pain crises are associated with high pain burden and increased rates of hospitalization. Strategies are needed to address health care disparities within gynecologic care in SCD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

39. Long‐term clinical outcomes and healthcare utilization of sickle cell disease patients with COVID‐19: A 2.5‐year follow‐up study.

Author

Feit, Avery, Gordon, Moshe, Alamuri, Tharun T., Hou, Wei, Mitchell, William B., Manwani, Deepa, and Duong, Tim Q.

Subjects
SICKLE cell anemia, COVID-19, TREATMENT effectiveness, MEDICAL care, BLOOD transfusion
Abstract

Objectives: This study investigated whether patients with sickle cell disease (SCD) had elevated risk of worse long‐term clinical outcomes and healthcare utilization 2.5 years post‐SARS‐CoV‐2 infection. Methods: This study consisted of 178 patients with SCD who tested positive for COVID‐19 between February 1, 2020 and January 30, 2022 in a major academic health system in New York City. The control cohort consisted of two‐to‐one matches of 356 SCD patients without a COVID‐19 positive test. The last follow‐up was July 18, 2022. The primary outcome was mortality. Secondary outcomes were annualized emergency department visits due to pain, pain hospital admission, length of stay due to pain, acute chest syndrome, episodic transfusion, and episodic exchange transfusion. Results: There was no significant difference in mortality between SCD patients with and without COVID‐19 (p >.05). There were no significant differences in secondary outcomes between pre‐ and postpandemic (p >.05). There were also no significant differences in these outcomes between SCD patients with and without COVID‐19 (p >.05). SCD care utilization was not significantly associated with COVID‐19 hospitalization status (p >.05). Conclusions: SCD patients with SARS‐CoV‐2 infection incurred no additional risk of worse long‐term outcomes compared to matched controls of SCD patients not infected by SARS‐CoV‐2. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Supplement to: A multinational trial of prasugrel for sickle cell vasoocclusive events.

Author

Van Damme, An, Dupont, Sophie, Philippet, Pierre, de Castro Lobo, Clarisse Lopes, Robitaille, Nancy, Tantawy, Azza AG, Mansour, Ahmed K, Al-Tonbary, Youssef, Badr, Mohamed, Elgawhary, Somaya, Ragab, Lamis, Hassab, Hoda, Mohamed El-Sayed, Hesham AF, Agbenyega, Tsiri E., Segbefia, Catherine I, Colombatti, Raffaella, Forni, Gian L, Masera, Nicoletta, Palazzi, Giovanni, Cesaro, Simone, Ogutu, Bernhards R, Oyieko, Janet N, Nduba, Videlis, Githanga, Jessie N, Abboud, Miguel R., Inati, Adlette, Alkindi, Salam S, Al Jaouni, Soad K., Unal, Selma, Sasmaz, Ilgen, Antmen, Ali B, Alzoebie, Azzam, Inusa, Baba, Rees, David, Will, Andrew, Dampier, Carlton, Heeney, Matthew M., Irwin, Robert G., Cohen, Debra, Quinn, Charles T., Krishnamurti, Lakshmanan, Rana, Sohail, Sarnaik, Sharada A., Smith-Whitley, Kim, Hoppe, Carolyn, Thompson, Alexis A., Boruchov, Donna M., Estepp, Jeremie Heath, Redding-Lallinger, Rupa, Strunk, Crawford, Piccone, Connie, Jeng, Michael, Whittle, John, Eng, Jennifer, Manwani, Deepa, Woods, Gerald, and Kanter, Julie

Published
2016

49. Consensus definition of essential, optimal, and suggested components of a pediatric sickle cell disease center.

Author

Hulbert, Monica L., Manwani, Deepa, Meier, Emily Riehm, Alvarez, Ofelia A., Brown, R. Clark, Callaghan, Michael U., Campbell, Andrew D., Coates, Thomas D., Frei‐Jones, Melissa J., Hankins, Jane S., Heeney, Matthew M., Hsu, Lewis L., Lebensburger, Jeffrey D., Quinn, Charles T., Shah, Nirmish, Smith‐Whitley, Kim, Thornburg, Courtney, and Kanter, Julie

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results